Nycomed Amersham has become the latest European biotech company to opt for a secondary listing on Nasdaq in the US.

Nycomed Amersham, a UK company which is already listed on the London Stock Exchange (LSE), said that it had filed with the US Securities & Exchange Commission to float APBiotech, its drug discovery unit, on the US market.